Anadys president and CEO Kleanthis Xanthopoulos to resign

By Elaine Rigoli

Tampa, Fla., June 14 - Anadys Pharmaceuticals, Inc. said its president and chief executive officer, Kleanthis G. Xanthopoulos, is resigning at the end of 2006 or sooner if a successor has been appointed.

Xanthopoulos, who will join San Diego-based Enterprise Partners Venture Capital as a managing director, will continue to serve as a board member of Anadys following his resignation.

The company also said it has promoted Steve Worland to the newly created post of president, pharmaceuticals, to lead all of Anadys' strategic planning, corporate development and research and development efforts.

Anadys is a biopharmaceutical company based in San Diego.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.